Amylyx Pharmaceuticals, Inc. AMLX
Institutional shares held
49.1 Million
281K
calls
438K
puts
Total value of holdings
$179M
$1.02M
calls
$1.59M
puts
Market Cap
$212M
58,533,200
Shares Out.
Institutional ownership
83.85%
# of Institutions
142
We take great care to ensure that the data presented and summarized in this overview for Amylyx Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMLX
View all-
Perceptive Advisors LLC New York, NY6.77MShares$24.6 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$16.9 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$9.77 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$9.69 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$8.81 Million0.0% of portfolio
-
Almitas Capital LLC Santa Monica, CA2.03MShares$7.38 Million3.73% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.97MShares$7.15 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY1.93MShares$7.01 Million0.52% of portfolio
-
Goldman Sachs Group Inc New York, NY1.86MShares$6.75 Million0.0% of portfolio
-
Abrdn PLC1.72MShares$6.25 Million0.01% of portfolio
Latest Institutional Activity in AMLX
Top Purchases
Top Sells
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AMLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2025
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+18.48%
|
-
|
|
Mar 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+24.86%
|
-
|
|
Mar 06
2025
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,851
+24.46%
|
-
|
|
Mar 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.15 P/Share
|
|
Mar 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,611
-1.19%
|
$4,833
$3.12 P/Share
|
|
Mar 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.17 P/Share
|
|
Feb 24
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,169
-3.0%
|
$12,507
$3.15 P/Share
|
|
Feb 05
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,310
+1.12%
|
$36,310
$1.57 P/Share
|
|
Feb 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,851
-0.37%
|
$35,553
$3.47 P/Share
|
|
Feb 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,678
-2.58%
|
$11,034
$3.49 P/Share
|
|
Feb 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,855
-0.37%
|
$35,565
$3.47 P/Share
|
|
Jan 24
2025
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
27,910
-3.25%
|
-
|
|
Jan 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,471
-0.23%
|
$29,884
$4.04 P/Share
|
|
Jan 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,471
-0.23%
|
$29,884
$4.05 P/Share
|
|
Dec 02
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,421
-3.77%
|
$27,105
$5.54 P/Share
|
|
Nov 04
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,690
+1.96%
|
$63,690
$1.57 P/Share
|
|
Sep 30
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,442
-7.37%
|
$34,326
$3.2 P/Share
|
|
Sep 30
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.57%
|
$55,767
$3.2 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.52M
Shares
From
11
Insiders
| Grant, award, or other acquisition | 1.19M shares |
|---|---|
| Open market or private purchase | 195K shares |
| Exercise of conversion of derivative security | 136K shares |
Sell / Disposition
158K
Shares
From
5
Insiders
| Open market or private sale | 131K shares |
|---|---|
| Bona fide gift | 27.9K shares |